Sign In
Buy IMNM
$22.76
-0.320 (-1.39%)
At Close: Jul 31, 2026
Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
10:11am, Tuesday, 14'th May 2024
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.35 per share a year ago.
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
08:00am, Tuesday, 14'th May 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu
Immunome to Present at 2024 Bank of America Healthcare Conference
08:00am, Wednesday, 08'th May 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg
Immunome Appoints Kinney Horn as Chief Business Officer
08:00am, Thursday, 02'nd May 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointmen
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
11:05am, Friday, 26'th Apr 2024
Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Immunome Appoints Sandra M. Swain to Board of Directors
08:26am, Thursday, 25'th Apr 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointmen
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will p
New Strong Sell Stocks for April 4th
07:01am, Thursday, 04'th Apr 2024
IMNM, SLOIF and TMQ have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.
Immunome: An Oncology Powerhouse In The Making
02:07pm, Tuesday, 02'nd Apr 2024
IMNM has acquired an anti-ROR1 antibody-drug conjugate, and ADC platform technology, from Zentalis Pharmaceuticals. IMNM has also acquired AL102 and AL101 from Ayala Pharmaceuticals. AL102 is already
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
04:02pm, Thursday, 28'th Mar 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
08:00am, Tuesday, 26'th Mar 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful
Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies
05:44am, Monday, 18'th Mar 2024
EDINBURGH, Scotland--(BUSINESS WIRE)--Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that its ArrayPlex™ discovery platform has been selected by Immunome, Inc. (NA
Immunome to Participate in the Leerink Partners Global Biopharma Conference
08:00am, Thursday, 07'th Mar 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
08:00am, Friday, 01'st Mar 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
04:05pm, Friday, 16'th Feb 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today annou
